IP Library Granted Patent US 12,440,618
Granted Patent B2
US 12,440,618 · App. 18/447,903 · Granted Oct 14, 2025

Wearable drug delivery device

Inventors: Ursina Streit (Kirchberg, CH); Roland Margot (Worb, CH); Jan Baumert (Grünen, CH); Simon Bosshard (Bern, CH); Michael Hanimann (Bern, CH); Fabian Steiner (Burgdorf, CH)
Assignee: TecMed AG
A61M5/14248A61M2005/14252A61M2207/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,440,618
App. No.
18/447,903
Granted
Oct 14, 2025
Kind
B2
Abstract

A drug delivery device for conducting a medical therapy includes a housing with an exit port opening, and an exit port assembly, where said exit port assembly includes a rigid exit port sealing holder and a soft exit port sealing, and provides both a fluid-tight closure of the exit port opening and a fluid-tight connection between the housing and the rigid exit port sealing holder.

Claims (40)

1. A drug delivery device, comprising:

a housing comprising at least two housing components configured to be attached to one another to form a protective shell of the drug delivery device;

a reservoir arranged inside the housing configured to contain a drug, the reservoir defining a fill port sealing cavity;

a fill port assembly configured for filling the reservoir;

a needle assembly comprising an input portion and an output portion; and

an exit port assembly, wherein:

the housing comprises an exit port opening to provide a passage for the output portion of the needle assembly from the inside of the housing to an exterior,

the exit port assembly comprises a first soft structure configured as a soft exit port sealing to provide a fluid-tight closure of the exit port opening of the housing,

the fill port assembly comprises a second soft structure configured as a fill port sealing, the fill port sealing arranged in the fill port sealing cavity to provide a fluid-tight closure of the fill port sealing cavity and is not operatively connected with the soft exit port sealing,

the fill port assembly and the exit port assembly are manufactured using a 2-shot injection molding process and are each configured as a unitary component with one or more of the at least two housing components, and

the housing further comprises a bottom wall defining another passage configured to receive the second soft structure such that the second soft structure is configured to be received by the another passage and fix the housing with respect to the reservoir, and wherein the bottom wall is arranged perpendicular to a wall of the housing comprising the exit port opening.

2. The drug delivery device according to claim 1 , wherein the housing is configured as a first housing unit and further comprises a bayonet connection configured for coupling with a second housing unit, and wherein a third soft structure is included in the bayonet connection.

3. The drug delivery device according to claim 1 , wherein the reservoir further comprises a reservoir outlet, and wherein a third soft structure is configured to couple the reservoir outlet to the needle assembly.

4. The drug delivery device according to claim 3 , wherein the housing further comprises a connector structure, and wherein a fourth soft structure is included in the connector structure.

5. The drug delivery device according to claim 4 , wherein the housing is configured as a first housing unit and the connector structure comprises a bayonet connection configured for coupling with a second housing unit, and wherein the fourth soft structure is included in the bayonet connection.

6. The drug delivery device according to claim 1 , wherein the housing further comprises a connector structure, and wherein a third soft structure is included in the connector structure.

7. The drug delivery device according to claim 6 , wherein the housing is configured as a first housing unit and the connector structure comprises a bayonet connection configured for coupling with a second housing unit, and wherein the third soft structure is included in the bayonet connection.

8. The drug delivery device of claim 1 , wherein the exit port assembly further comprises a rigid exit port sealing holder comprising an exit port channel configured to receive the output portion of the needle assembly, wherein the soft exit port sealing is configured to attach to the rigid exit port sealing holder.

9. A drug delivery device, comprising:

a housing comprising at least two housing components configured to be attached to one another to form a protective shell of the drug delivery device;

a reservoir arranged inside the housing configured to contain a drug, the reservoir configured with an opening for receiving a piston;

a needle assembly comprising an input portion and an output portion; and

an exit port assembly, wherein:

the housing comprises an exit port opening to provide a passage for the output portion of the needle assembly from the inside of the housing to an exterior,

the exit port assembly comprises a first soft structure configured as a soft exit port sealing to provide a fluid-tight closure of the exit port opening of the housing,

the housing comprises a connector structure arranged coaxially with the opening of the reservoir,

the connector structure comprises a second soft structure not operatively connected with the soft exit port sealing,

the exit port assembly and the connector structure are manufactured using a 2-shot injection molding process and are each configured as a unitary component with one or more of the at least two housing components, and

the housing is configured as a first housing unit and the connector structure comprises a bayonet connection configured for coupling with a second housing unit, and wherein the second soft structure is included in the bayonet connection.

10. A drug delivery device, comprising:

a housing comprising at least two housing components configured to be attached to one another to form a protective shell of the drug delivery device;

a reservoir arranged inside the housing configured to contain a drug, the reservoir configured with an opening for receiving a piston;

a needle assembly comprising an input portion and an output portion; and

an exit port assembly, wherein:

the housing comprises an exit port opening to provide a passage for the output portion of the needle assembly from the inside of the housing to an exterior,

the exit port assembly comprises a first soft structure configured as a soft exit port sealing to provide a fluid-tight closure of the exit port opening of the housing,

the housing comprises a connector structure arranged coaxially with the opening of the reservoir,

the connector structure comprises a second soft structure not operatively connected with the soft exit port sealing,

the exit port assembly and the connector structure are manufactured using a 2-shot injection molding process and are each configured as a unitary component with one or more of the at least two housing components, and

the housing is configured as a first housing unit and comprises a locking structure configured for coupling with a second housing unit, and wherein a third soft structure is included in the locking structure.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2026
From: MYLIFE GROUP AG
To: MYLIFE DIABETES CARE AG
Reel/Frame 074110/0683 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 10, 2023
From: STREIT, URSINA; MARGOT, ROLAND; BAUMERT, JAN; BOSSHARD, SIMON; HANIMANN, MICHAEL; STEINER, FABIAN
To: TECMED AG
Reel/Frame 064555/0904 →
Priority Claims (1)
EP 20181604 · Jun 23, 2020 · regional
Continuity (2)
Continuation 17352669 · Jun 21, 2021
Related Publication 20230381408A1 · Nov 30, 2023
References Cited (29)
US 5597990A · Carvalho et al. · 1997 [cited by applicant]
US 6537250B1 · Kriesel · 2003 [cited by applicant]
US 6669668B1 · Kleeman et al. · 2003 [cited by applicant]
US 6699218B2 · Flaherty et al. · 2004 [cited by applicant]
US 6749587B2 · Flaherty · 2004 [cited by applicant]
US 7018360B2 · Flaherty et al. · 2006 [cited by applicant]
US 7303549B2 · Flaherty et al. · 2007 [cited by applicant]
US 7771412B2 · Anderson et al. · 2010 [cited by applicant]
US 8187232B2 · Chong · 2012 [cited by examiner]
US 8393357B2 · Chong et al. · 2013 [cited by applicant]
US 8679062B2 · Yodfat et al. · 2014 [cited by applicant]
US 9061097B2 · Holt · 2015 [cited by examiner]
US 9463309B2 · Yavorsky et al. · 2016 [cited by applicant]
US 9993595B2 · Michaud et al. · 2018 [cited by applicant]
US 11759564B2 · Streit · 2023 [cited by examiner]
US 20180353742A1 · Wehbe · 2018 [cited by applicant]
US 20190091404A1 · Nazzaro et al. · 2019 [cited by applicant]
US 20210393871A1 · Streit et al. · 2021 [cited by applicant]
US 20210393872A1 · Streit et al. · 2021 [cited by applicant]
US 20210393873A1 · Streit et al. · 2021 [cited by applicant]
CA 2625954A1 · 2007 [cited by applicant]
EP 1390089B1 · 2007 [cited by applicant]
EP 1682203B1 · 2010 [cited by applicant]
EP 3251585A1 · 2017 [cited by applicant]
EP 3443996A1 · 2019 [cited by applicant]
EP 3636298A1 · 2020 [cited by applicant]
WO 03103763A1 · 2003 [cited by applicant]
WO WO2012072555A1 · 2012 [cited by examiner]
WO 2017120251A1 · 2017 [cited by applicant]